Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Recipient : NRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, the companies will jointly develop intravenous NRX-100 (ketamine hydrochloride) and is being developed to treat suicidal depression.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 11, 2023
Lead Product(s) : Ketamine Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Recipient : NRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Rho Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2021
Lead Product(s) : Tiotropium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Rho Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2014
Lead Product(s) : Latanoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable